Literature DB >> 17001156

Pleomorphic giant cell adenocarcinoma of the prostate: report of 6 cases.

Anil V Parwani1, Mehsati Herawi, Jonathan I Epstein.   

Abstract

Pleomorphic tumors with giant cells have been described in a variety of primary sites. However, only a few cases have been described among prostatic carcinomas with only 1 on diagnostic biopsy material. Five cases were retrieved from the consultation files of one of the authors. One of the cases was retrieved from the surgical pathology files at our institute. Patient ranged in age from 59 to 76 years (mean=65.8 y). The diagnosis was made on needle biopsy (n=3), urethral biopsy (n=1), transurethral resection (n=1), or radical prostatectomy (n=1). In all cases, giant, bizarre, anaplastic cells were present. In 4 of the cases, marked pleomorphism occupied 5% of the specimen, with 20% and 70% bizarre giant cells in the other 2 cases. In one case, the bizarre cells had atypical mitotic figures, with other cases showing no mitoses in the markedly pleomorphic cells. In addition to the pleomorphic giant cell component, multiple coexistent histologic components were seen including Gleason score 9 conventional prostate cancer (n=6), small cell carcinoma (n=1), squamous carcinoma (n=1), and prominent ductal adenocarcinoma differentiation with intraductal spread (n=1). Immunohistochemically, 4 cases were for negative for prostate-specific antigen in the giant cells, 1 had 5% staining, and the other had 50% positivity in the giant cells. Staining for prostate-specific antigen in the conventional prostate carcinoma component was 1%, 5%, 20%, 50%, 100%, and 100%. The bizarre giant cells were strongly positive for cytokeratins AE1/AE3 and/or Cam 5.2 (n=3). Two cases had a history of conventional prostate cancer 4 years before the giant cell component, 1 treated with Lupron and the other with radiation. Follow-up after diagnosis of the giant cell component: Case 1: dead in 1 year of disease; Case 2: progressive metastases in 2 years; Case 3: alive at 1 year with disease; Case 4: large perineal recurrence after brachytherapy at 3 years; Case 5: radical prostatectomy with extraprostatic extension and seminal vesicle invasion; and Case 6: alive at 3 months, free of disease. Conventional prostate cancer, even when very high grade, typically consists of cells with relatively uniform nuclei. Our study expands the histology described in prostate cancer to include in very rare cases with prominent pleomorphism and bizarre giant cells. This giant cell component heralds a particularly aggressive clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17001156     DOI: 10.1097/01.pas.0000209841.77595.4b

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  14 in total

1.  Formation of solid tumors by a single multinucleated cancer cell.

Authors:  Zhang Weihua; Qingtang Lin; Asa J Ramoth; Dominic Fan; Isaiah J Fidler
Journal:  Cancer       Date:  2011-03-01       Impact factor: 6.860

2.  HOXB13 is not expressed in pleomorphic giant cell carcinoma of the bladder.

Authors:  Valeria Barresi
Journal:  Virchows Arch       Date:  2018-06-21       Impact factor: 4.064

Review 3.  The pathology of unusual subtypes of prostate cancer.

Authors:  Jing Li; Zhe Wang
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

4.  DNA damage repair alterations are frequent in prostatic adenocarcinomas with focal pleomorphic giant-cell features.

Authors:  Tamara L Lotan; Harsimar B Kaur; Abdullah M Alharbi; Colin C Pritchard; Jonathan I Epstein
Journal:  Histopathology       Date:  2019-04-01       Impact factor: 5.087

5.  Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer.

Authors:  Catherine O'Brien; Lawrence D True; Celestia S Higano; Brooks L S Rademacher; Mark Garzotto; Tomasz M Beer
Journal:  Am J Clin Pathol       Date:  2010-04       Impact factor: 2.493

Review 6.  HOXB13 a useful marker in pleomorphic giant cell adenocarcinoma of the prostate: a case report and review of the literature.

Authors:  Laura Larnaudie; Eva Compérat; Pierre Conort; Justine Varinot
Journal:  Virchows Arch       Date:  2017-05-08       Impact factor: 4.064

Review 7.  Histopathology of Prostate Cancer.

Authors:  Peter A Humphrey
Journal:  Cold Spring Harb Perspect Med       Date:  2017-10-03       Impact factor: 6.915

8.  Fine needle aspiration biopsy of an osteoclast-rich undifferentiated urothelial carcinoma: A cytology case report and review of the literature.

Authors:  Marilyn M Bui; Chetna N Purohit; Ardeshir Hakam
Journal:  Cytojournal       Date:  2010-09-17       Impact factor: 2.091

9.  Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung.

Authors:  Alex Chang; Ali Amin; Edward Gabrielson; Peter Illei; Richard B Roden; Rajni Sharma; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2012-10       Impact factor: 6.394

10.  HOXB13 protein expression in metastatic lesions is a promising marker for prostate origin.

Authors:  Justine Varinot; Adéline Furudoï; Sarah Drouin; Véronique Phe; Raphaele Renard Penna; Morgan Roupret; Marc-Olivier Bitker; Olivier Cussenot; Eva Compérat
Journal:  Virchows Arch       Date:  2016-03-01       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.